Full-Time
Semantic AI Engineer
Updated on 9/4/2026
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
Compensation Overview
$78.5k - $141k/yr
North Chicago, IL, USA
Hybrid
Bachelor's, Master's
 Software Engineering (1) |
|---|
Get referred to AbbVie
See people who can refer or advise you
- A bachelor's degree in Data Science, Computer Science, Informatics, Software Engineering, Semantic Technologies, or a related field and five years of experience, or a master's degree and four years of experience.
- Demonstrated experience building production-quality data, software, artificial intelligence, or semantic technology solutions, including APIs, MCP tools, agents, services, integrations, reusable platform components, common technologies, and formats such as REST APIs, XML, JSON, and Python libraries such as Pydantic.
- Working knowledge of ontologies, controlled vocabularies, knowledge graphs, semantic standards including OWL, RDF, and SPARQL, metadata, mapping, normalization, and FAIR data principles.
- Ability to translate business and governance requirements into scalable technical designs that make semantic assets accessible to applications, artificial intelligence agents, search, and data integration workflows.
- Demonstrated ability to learn and apply emerging technologies, operate within timelines, produce clear technical documentation for enterprise adoption, and contribute to continuous integration and continuous delivery practices that enable reliable delivery and ongoing operational support.
- Strong collaboration, stakeholder management, and communication skills, with the ability to work across platform, governance, ontology, and product teams.
- Ability to work in a fast-paced, highly collaborative, dynamic work environment with constantly shifting priorities.
- Ability to work cross-functionally and in interdisciplinary teams and communicate effectively, both verbally and in writing, with scientists and non-scientists.
- Fluency in English.
- Design, build, and operationalize artificial-intelligence-driven semantic solutions that embed enterprise ontologies and semantic assets into the Enterprise Product Master Data initiative, the Dataverse, and related enterprise platforms through Enterprise Ontology Services.
- Engineer and translate ontologies, controlled vocabularies, mappings, semantic contracts, and reference standards into machine-consumable services, APIs, agent tools, and reusable software components.
- Enable semantic knowledge structures to drive inference, search, normalization, query expansion, entity resolution, and data integration across enterprise-scale workflows.
- Partner with the Standards and Governance Expert to define implementation patterns, decision processes, and quality gates that embed FAIR data principles into SHIFT-generated software assets from project initiation.
- Collaborate with platform, product, data, ontology, and governance teams to align semantic services with business requirements, enterprise architecture, and scalable delivery practices.
- Develop and maintain technical documentation, integration patterns, reusable examples, and guidance that help teams consume Enterprise Ontology Services capabilities consistently and effectively.
- Adhere to applicable corporate standards, including the code of conduct, data security, GxP compliance where relevant, software development lifecycle expectations, and responsible artificial intelligence practices.
- Monitor new technology trends relevant to knowledge analysis and insights discovery.
- Innate scientific curiosity, technical creativity, and innovative thinking, with motivation to advance information analysis and insights generation.
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $16.99 billion, up 10.2%, and adjusted EPS reached $3.65.
- FDA approved Decnupaz in May 2026, AbbVie’s first hematology ADC.
- European approvals for Rinvoq in vitiligo and alopecia expand 2026 commercial reach.
What critics are saying
- Imbruvica faced Medicare price cuts in 2026, accelerating oncology erosion and reimbursement pressure.
- Oncology revenue fell 2.4% in Q2 2026 as Imbruvica dropped 29.4%.
- Skyrizi-Rinvoq concentration leaves AbbVie vulnerable if one safety signal emerges.
What makes AbbVie unique
- AbbVie’s Skyrizi and Rinvoq generated enough growth to replace Humira by 2025.
- AbbVie now pairs immunology scale with oncology assets like Epkinly, Emrelis, and Decnupaz.
- Apogee’s 2026 deal adds late-stage IL-13 and TSLP antibodies for eczema and asthma.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 5%AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.
The Manufacturers Life Insurance Company acquired a $655.27 million stake in AbbVie Inc., according to its latest SEC Form 13F filing. Other institutional investors also increased their positions significantly during the same period. Norges Bank acquired a new $5.87 billion position, whilst Wellington Management Group boosted its holdings by 457.4%. AbbVie reported quarterly earnings per share of $3.65, exceeding forecasts, with revenue growth of 10.2% year over year. The company generated $16.99 billion in revenue last quarter, surpassing expectations. Equity analysts maintain a bullish outlook. Barclays, Wolfe Research, and BMO Capital Markets each set price targets of $300, with ratings of "overweight" or "outperform". The consensus rating is "Moderate Buy". Institutional investors currently hold 70.23% of AbbVie's shares, reflecting confidence in the biopharmaceutical company's strategy and performance.
AAPS PharmSci 360: CMC strategies, part 1. In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy. PharmTech spoke with Alfred Rumondor, PhD, CMC due diligence for external assets at AbbVie, and Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb, to learn more about their upcoming panel discussion, Navigating CMC Strategy in the Current Landscape, at, which is being held from October 25-28 in New Orleans. In part 1 of this 3-part interview, Rumondor and Singh discussed how chemistry, manufacturing, and controls (CMC) review practices are evolving and what that means for manufacturing strategy. Singh identified the most consequential shift as a move from informal, reviewer-dependent flexibility to formal, risk-based flexibility applied consistently across the product life cycle. She pointed to Operation TrailBlazer and updated phase 1 CMC guidance as examples, stating they are reducing required manufacturing data pre-investigational new drug application (IND). Singh also pointed out that cell and gene therapy programs no longer need 3 independent process performance qualification batches and can flex specifications for small-batch production. AI-driven tools and emerging credibility frameworks are reinforcing this trend by helping generate cleaner data packages for faster, more consistent regulatory decisions. Singh cautioned, however, that companies must build "risk justification muscle" rather than simply accepting flexibility at face value. Reduced requirements should be treated as deferral, not elimination, of data obligations; organizations need clear plans for when deferred data will be generated and which milestones trigger it. She emphasized investing early in comparability infrastructure, leveraging platform and prior-knowledge pathways, and engaging proactively with regulators. Rumondor addressed the pressure to compress development timelines. He argued the real question isn't whether compression is safe, but how to do it properly by working smarter rather than skipping steps. He cited premature form selection without adequate screening as a common shortcut that later may bring costly bridging and comparability studies, increasing both timeline and program risk. Compressed timelines are achievable, but only when teams rigorously plan the full development path upfront, according to Rumondor. About the speakers. Alfred Rumondor, PhD, is Director, Development Sciences Licensing and Acquisitions, at AbbVie. Dr. Swita Singh holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.
AbbVie's experimental cancer drug etentamig achieved a 74% overall response rate in a pivotal Phase 3 trial for relapsed or refractory multiple myeloma, significantly outperforming standard treatments at 45.7%. The study also met its progression-free-survival endpoint. The drug remains investigational pending regulatory review. AbbVie's oncology division reported $1.65 billion in second-quarter revenue, down 1.5%, representing roughly 9.7% of total sales. Venclexta grew 11.6%, whilst Imbruvica declined 29.4%. AbbVie shares traded at $260.445. The company requires new growth drivers as its existing oncology portfolio faces mixed performance. Detailed safety and durability data have not yet been disclosed.
Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.